Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Authors:
Open Access
- 13 October 2016
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 5 (11) , 3176-3185
Abstract
Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory metastatic colorectal cancer. In clinical studies, steady‐state exposure to the M‐2 and M‐5 metabolites of regorafenib was similar to that of the parent drug; however, the contribution of these metabolites to the overall observed clinical activity of regorafenib cannot be investigated in clinical trials. Therefore, we assessed the pharmacokinetics and pharmacodynamics of regorafenib, M‐2, and M‐5 in vitro and in murine xenograft models. M‐2 and M‐5 showed similar kinase inhibition profiles and comparable potency to regorafenib in a competitive binding assay. Inhibition of key target kinases by all three compounds was confirmed in cell‐based assays. In murine xenograft models, oral regorafenib, M‐2, and M‐5 significantly inhibited tumor growth versus controls. Total peak plasma drug concentrations and exposure to M‐2 and M‐5 in mice after repeated oral dosing with regorafenib 10 mg/kg/day were comparable to those in humans. In vitro studies showed high binding of regorafenib, M‐2, and M‐5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma. Estimated free plasma concentrations of regorafenib and M‐2, but not M‐5, exceeded the IC50 at human and murine VEGFR2, suggesting that regorafenib and M‐2 are the primary contributors to the pharmacologic activity of regorafenib in vivo.Keywords
Funding Information
- Bayer
This publication has 21 references indexed in Scilit:
- Protein Binding: Do We Ever Learn?Antimicrobial Agents and Chemotherapy, 2011
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung CancerCancer Discovery, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discoveryNature Reviews Drug Discovery, 2010
- GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 SignalingCancer Research, 2010
- Significance of Protein Binding in Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2010
- Growth factors in tumor microenvironmentFrontiers in Bioscience-Landmark, 2010
- N-Glycosylation of Fibroblast Growth Factor Receptor 1 Regulates Ligand and Heparan Sulfate Co-receptor BindingJournal of Biological Chemistry, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- High-throughput determination of the free fraction of drugs strongly bound to plasma proteinsJournal of Pharmaceutical Sciences, 2004